NCT00944268

Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety

Clinical Study Phase III, Multicenter, Prospective, Open to Evaluate the Efficacy and Tolerability of the Combination Use of Passiflora Incarnata L, Crataegus Oxyacantha and Salix Alba L in Mild and Moderate Anxiety

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 124 (estimated)
• Sponsor: Ativus Farmaceutica Ltda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and tolerability of the combination use of Passiflora incarnata L, Crataegus oxyacantha and Salix alba L in mild and moderate anxiety. Clinical study phase III, multicenter, prospective, open. Patients will be included in sufficient quantity to achieve the minimum number of 124 evaluable patients.

Conditions

• Anxiety
• Efficacy
• Tolerability

Interventions

Type	Name	Description
DRUG	Passiflora, Crataegus e Salix	Comparison of different pharmaceutics forms of drug

Timeline

• Start date: 2009-09-01
• Primary completion: 2009-12-01
• Completion: 2010-01-01
• First posted: 2009-07-23
• Last updated: 2009-07-24

Locations

1 site across 1 country: Brazil